Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates.

IF 6.1 2区生物学 Q1 CELL BIOLOGY

Cell Death Discovery Pub Date : 2025-04-05 DOI:10.1038/s41420-025-02429-5

Qingling Yin, Yanlong Zhang, Xueqing Xie, Meijun Hou, Xunsheng Chen, Jie Ding

引用次数: 0

Abstract

Gastric cancer, marked by its high incidence and poor prognosis, demands the urgent development of novel and effective treatment strategies, especially for patients ineligible for surgery or those who have had limited success with chemotherapy, radiotherapy and targeted therapies. Recently, antibody-drug conjugates (ADCs) have become a key area of investigation due to their high specificity and potent antitumor effects. These therapies combine monoclonal antibodies, designed to bind to tumor-specific antigens, with cytotoxic agents that selectively target and destroy malignant cells. ADCs have generated significant interest in clinical trials as a promising approach to improve both treatment efficacy and patient outcomes in gastric cancer. However, their clinical application is not without challenges and limitations that must be addressed. This review discusses the recent progress in the use of ADCs for gastric cancer treatment.

查看原文本刊更多论文

导航胃癌治疗的未来：抗体-药物偶联物影响的综述。

胃癌发病率高、预后差，迫切需要开发新颖有效的治疗策略，特别是对于不适合手术治疗或化疗、放疗和靶向治疗成功率有限的患者。近年来，抗体-药物偶联物（adc）因其高特异性和有效的抗肿瘤作用而成为研究的热点。这些疗法结合了单克隆抗体，设计用于结合肿瘤特异性抗原，与选择性靶向和破坏恶性细胞的细胞毒性药物。adc作为一种有希望改善胃癌治疗疗效和患者预后的方法，在临床试验中引起了极大的兴趣。然而，它们的临床应用并非没有挑战和限制，必须加以解决。本文综述了adc在胃癌治疗中的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Death Discovery Biochemistry, Genetics and Molecular Biology-Cell Biology

CiteScore

8.30

自引率

1.40%

发文量

468

审稿时长

9 weeks

期刊介绍： Cell Death Discovery is a multidisciplinary, international, online-only, open access journal, dedicated to publishing research at the intersection of medicine with biochemistry, pharmacology, immunology, cell biology and cell death, provided it is scientifically sound. The unrestricted access to research findings in Cell Death Discovery will foster a dynamic and highly productive dialogue between basic scientists and clinicians, as well as researchers in industry with a focus on cancer, neurobiology and inflammation research. As an official journal of the Cell Death Differentiation Association (ADMC), Cell Death Discovery will build upon the success of Cell Death & Differentiation and Cell Death & Disease in publishing important peer-reviewed original research, timely reviews and editorial commentary. Cell Death Discovery is committed to increasing the reproducibility of research. To this end, in conjunction with its sister journals Cell Death & Differentiation and Cell Death & Disease, Cell Death Discovery provides a unique forum for scientists as well as clinicians and members of the pharmaceutical and biotechnical industry. It is committed to the rapid publication of high quality original papers that relate to these subjects, together with topical, usually solicited, reviews, editorial correspondence and occasional commentaries on controversial and scientifically informative issues.